Andrew Charles

1 month ago | neurologylive.com | Andrew Charles |Isabella Ciccone

WATCH TIME: 5 minutes "These are the first preventive therapies that have been developed specifically for migraine based on a really solid foundation of science." In April 2024, the American Headache Society (AHS) updated its position statement on calcitonin gene-related peptide (CGRP)-targeting therapies for migraine prevention.1 Unlike previous first-line therapies, which were initially developed for other conditions, CGRP-targeting treatments were specifically designed based on a solid...

1 month ago | pharmacytimes.com | Luke Halpern |Andrew Charles

CommentaryVideoApril 6, 2025Author(s):,Andrew Charles, MD, outlines why calcitonin-gene-related peptide (CGRP) antagonists are increasingly favored as first-line migraine treatments and how pharmacists play a key role in patient education and support.

Nov 15, 2024 | msn.com | Andrew Charles |Lisa Smith |Michael Yang

Continue reading More for You   Continue reading More for You

Dec 26, 2023 | cowen.com | Oliver Chen |John Kernan |John W. Blackledge |Andrew Charles

, , , , , , , and Insight by TD Cowen identifies the implementation of marketplaces, integrated advertising, and artificial intelligenas as the new nexus of retail. These advancements are most important for traditional brick-and-mortar stores given existing scale and the opportunity to increase customer relevance. Each element of the new nexus will drive incremental revenue, profitability, and customer satisfaction.

Jul 17, 2023 | cowen.com | Oliver Chen |John Kernan |Andrew Charles

During the 7th Annual Future of the Consumer Conference, industry leaders driving innovation through agility, creativity, and purpose spoke with our consumer analysts on the TD Cowen Insights Podcast.